Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
April 23, 2021 at 08:07 am EDT
Share
Honz Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 921.642 million compared to CNY 1,008.431 million a year ago. Operating income was CNY 58.021 million compared to operating loss of CNY 19.092 million a year ago. Net income was CNY 9.339 million compared to net loss of CNY 26.462 million a year ago. Basic earnings per share from continuing operations was CNY 0.0208 compared to basic loss per share from continuing operations of CNY 0.0588 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
HONZ PHARMACEUTICAL CO., LTD. 